parallel approaches may be necessary and may already be used by GPs in clinical practice. In one approach the GP could ask in a first step if chest pain is caused by myocardial ischaemia and, if the answer is yes, decide on a second step if the situation should be classified as 'acute' or 'stable'. In another approach GPs may ask in every patient with chest pain if there are any red flags indicative for ACS or other conditions requiring urgent admission to hospital. While the MHS aims to support the first approach it does not substitute the second.
Lastly, Djasmo et al state that our study does not prove that the MHS performs better than GPs' own judgment based on common practice. We agree that such a comparison would be an important step in the evaluation of the MHS. Even more interesting would be an impact study investigating the effect of using the MHS on outcomes relevant to patients, like mortality. However, the primary aim of our study was to test the robustness of the MHS. We are currently working on an analysis comparing different diagnostic strategies based on the MHS, GPs' assessments, and combinations of both. Since this will be a secondary analysis and since the study was not powered to answer these questions, results will be explanatory. A major concern in future studies will be the sample size. Let us assume that the sensitivity of GPs' assessments would be 85% and that an increase in sensitivity of 5% would be judged as clinically relevant. Based on these assumptions, and the prevalence of CHD in primary care, a sample size of about 6000 patients would be necessary to compare these two diagnostic tests in an adequately powered study using a paired design.
7 Necessary sample sizes for impact studies using outcomes relevant to patients may even be higher. We are not sure if these studies will ever be conducted and assume that recommendations must be based on the limited evidence we have so far. Martina Kelly describes well the ways in which doctors use their sense of smell, including in recognising infection. 1 As well as the infections she describes, I would suggest that from my experience there can be a distinct smell in a patient with some upper and lower respiratory tract infections. When my son was 2-yearsold he developed rapid onset of fever, earache, and he smelt distinctly 'bacterially infected'. It was the latter that made me seek medical attention the same evening. He was prescribed amoxicillin and within 12 hours was afebrile, in less pain, and no longer smelt as if he was rotting; he went to nursery and I went to work. I had a clear conscience believing that he did not have a viral infection that he may spread to his peers at nursery.
Perhaps related, I know that taste comes into my decision making to use antibiotics.
If a patient describes their sputum or nasal discharge as tasting foul I am more likely to resort to prescribing antibiotics. There will sometimes be an associated odour in such cases.
In this age of guidelines rightly helping us to limit our use of antibiotics, I wonder if smell would be a helpful sign to contribute to decision making. However, I suspect it will never end up in the guidelines due to a lack of randomised controlled trials to provide the evidence required.
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